Prism Clinical Imaging and Sora Neuroscience Announce Cooperation Agreement

Cooperating in Advanced MRI Technology for Diagnosis and Treatment Planning of Brain Disorders

ELM GROVE, WI / ACCESSWIRE / August 20, 2024 / Prism Clinical Imaging, Inc. (Prism), experts in brain mapping software and applications, and Sora Neuroscience, Inc. (Sora), a brain imaging technology company, today announced a letter of cooperation to assist one another in performing validation testing and commercialization of products for brain resting state functional MRI (rs-fMRI) analysis.

Sora Neuroscience is licensee of a portfolio of resting state network mapping technology developed and clinically investigated at Washington University in St. Louis (WashU) over the past decade. These machine learning algorithms have been trained for brain tumor and epilepsy patient surgery planning. Prism provides clinical software and web-based services for acquisition, analysis, display, and export of functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), and other data. It also provides tools to combine fMRI and DTI with other imaging such as PET.

These technologies identify critical spatial relationships and functional structures to avoid during treatment, such as surgery.

About Prism Clinical Imaging

Prism Clinical Imaging, Inc., provides clinicians with imaging tools to diagnose and plan treatment for brain disorders including tumors, epilepsy, and other neurological disorders. Deployment options range from on-premises to cloud-based. Please visit www.prismclinical.com for further information. Follow Prism on LinkedIn and Twitter, @PrismClinical.

Contact: James L. Reuss, PhD (CEO), jreuss@prismclinical.com

About Sora Neuroscience, Inc.

Sora Neuroscience, Inc. is a brain imaging technology company committed to providing clinically useful and rigorously tested resting state functional MRI analysis tools ready to be integrated into existing clinical workflows. Sora was founded by leading resting state fMRI innovators at Washington University in St. Louis (WashU) and is headquartered in Minneapolis, Minnesota. For more information, please visit www.soraneuroscience.com.

Contact: Stephen R. Schaefer, JD (CEO), steve@soraneuroscience.com

SOURCE: Prism Clinical Imaging, Inc.

View the original press release on accesswire.com

Staff

Recent Posts

Press Release for The Changing Face of Addiction VIRTUAL Summit

Join us for an enlightening and transformative experience at the Changing Face of Addiction Virtual…

2 hours ago

Anju to Highlight Newly Launched MA Knowledge at DIA MICC 2024 in London

CHICAGO, Sept. 19, 2024 /PRNewswire/ -- Anju, a leading provider of adaptive life sciences software solutions,…

8 hours ago

Dana-Farber Cancer Institute Partners with Clinical.ly to Enhance Regulatory Operations with eReg Solutions

NEW YORK, Sept. 19, 2024 /PRNewswire/ -- The Dana-Farber Cancer Institute, a world leader in cancer…

8 hours ago

Danaher Schedules Third Quarter 2024 Earnings Conference Call

WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its…

8 hours ago

CS Genetics Partners with ROSALIND® to Democratize Single-Cell Genomics

Life Science Innovators Partner to Transform the Samples-to-Insight Cycle SAN DIEGO, Sept. 19, 2024 /PRNewswire/…

8 hours ago